Published in Lab Invest on August 01, 1995
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2011) 2.03
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol (1998) 1.90
microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun (2014) 1.41
The latent transforming growth factor beta binding protein (LTBP) family. Biochem J (2000) 1.27
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A (2011) 1.17
Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res (2009) 1.14
Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res (2012) 0.92
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol (2011) 0.86
Ovary and fimbrial stem cells: biology, niche and cancer origins. Nat Rev Mol Cell Biol (2015) 0.86
Current status of bevacizumab in advanced ovarian cancer. Onco Targets Ther (2013) 0.85
Glycomic analysis of membrane glycoproteins with bisecting glycosylation from ovarian cancer tissues reveals novel structures and functions. J Proteome Res (2014) 0.83
Latent transforming growth factor β-binding protein 4 is downregulated in esophageal cancer via promoter methylation. PLoS One (2013) 0.81
Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res (2002) 0.80
Latent transforming growth factor binding protein 4 (LTBP4) is downregulated in mouse and human DCIS and mammary carcinomas. Cell Oncol (Dordr) (2011) 0.79
Sphingosine kinase 1 is required for TGF-β mediated fibroblastto- myofibroblast differentiation in ovarian cancer. Oncotarget (2016) 0.78
Analysis of TGF-B and TGF-B-RII in Thyroid Neoplasms from the United States, Japan, and China. Endocr Pathol (1998) 0.77
TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (1997) 15.75
Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science (1997) 9.53
Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J (1998) 9.36
ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep (2001) 5.32
Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science (1999) 4.69
Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A (1987) 4.53
TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J (1997) 4.48
Smad6 inhibits signalling by the TGF-beta superfamily. Nature (1997) 4.34
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol (2011) 4.22
Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem (2001) 4.22
Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A (2000) 4.08
ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell (1998) 3.98
Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature (1988) 3.96
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol (1989) 3.89
Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (1989) 3.80
Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell (1993) 3.57
Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem (1994) 3.49
Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell (1999) 3.27
Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J (1999) 3.22
Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res (1992) 3.15
The L45 loop in type I receptors for TGF-beta family members is a critical determinant in specifying Smad isoform activation. FEBS Lett (1998) 3.00
Characterization of type I receptors for transforming growth factor-beta and activin. Science (1994) 2.94
Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev (1998) 2.56
Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest (1999) 2.50
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology (2005) 2.49
Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol (1997) 2.46
TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. Cell (1990) 2.46
Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem (1999) 2.44
Basic gait parameters: reference data for normal subjects, 10-79 years of age. J Rehabil Res Dev (1993) 2.43
BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol (2000) 2.40
Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol (1995) 2.36
c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem (1999) 2.32
The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia (1978) 2.31
A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A (2000) 2.31
A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun (1986) 2.24
Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem Sci (2000) 2.24
Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J (1998) 2.20
Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene (1993) 2.19
Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci U S A (1995) 2.19
Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol (1994) 2.15
Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. Endocrinology (1995) 2.12
Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med (1985) 2.12
Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J Biol Chem (1999) 2.12
Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem (1987) 2.06
Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet (1990) 2.04
Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell (2000) 2.01
BMP2-mediated alteration in the developmental pathway of fetal mouse brain cells from neurogenesis to astrocytogenesis. Proc Natl Acad Sci U S A (2001) 2.01
Noggin is required for induction of the hair follicle growth phase in postnatal skin. FASEB J (2001) 1.95
Smad6 is a Smad1/5-induced smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J Biol Chem (2000) 1.87
Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science (1999) 1.85
Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet (1998) 1.78
Left-right asymmetric expression of lefty2 and nodal is induced by a signaling pathway that includes the transcription factor FAST2. Mol Cell (2000) 1.78
Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res (1998) 1.75
Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. J Rheumatol (1996) 1.73
Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem (1996) 1.72
Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A (1988) 1.71
Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J Cell Biol (1993) 1.71
ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene (1999) 1.70
Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol Cell Biol (2001) 1.69
Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol Biol Cell (2001) 1.69
Transforming growth factor-beta/Smads signaling induces transcription of the cell type-restricted ankyrin repeat protein CARP gene through CAGA motif in vascular smooth muscle cells. Circ Res (2001) 1.66
Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia (1989) 1.66
Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol Biol Cell (2000) 1.66
Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-beta. J Biol Chem (1994) 1.61
[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol (1994) 1.61
Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci (1999) 1.61
Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet (1999) 1.61
Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene (2008) 1.59
Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor. J Cell Sci (2001) 1.59
Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol (1995) 1.58
Concomitant in vivo production of 19 different cytokines in human tonsils. Immunology (1994) 1.57
TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP. Oncogene (2011) 1.53
Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. J Cell Sci (2001) 1.53
A role for Id in the regulation of TGF-beta-induced epithelial-mesenchymal transdifferentiation. Cell Death Differ (2004) 1.51
Neurotrophic activity of platelet-derived growth factor (PDGF): Rat neuronal cells possess functional PDGF beta-type receptors and respond to PDGF. Proc Natl Acad Sci U S A (1991) 1.50
Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Curr Opin Cell Biol (1996) 1.50
Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. J Nucl Med (2000) 1.50
The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer (2001) 1.48
Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab (1986) 1.47
Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab (1992) 1.47
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat. J Neuropathol Exp Neurol (1998) 1.46
HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat Genet (1998) 1.45
Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res (1993) 1.45
Amyloid in polypeptide hormone-producing tumors. Lab Invest (1977) 1.45
Localization of transforming growth factor beta 1 and its latent binding protein in human chronic pancreatitis. Gastroenterology (1995) 1.44
The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling. J Cell Biol (2001) 1.44
Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res (1996) 1.44
Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg (1987) 1.41
Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab (2005) 1.40
Platelet-derived growth factor is angiogenic in vivo. Growth Factors (1992) 1.40
Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein. J Biol Chem (1994) 1.39
Role of apoptosis signal-regulating kinase in regulation of the c-Jun N-terminal kinase pathway and apoptosis in sympathetic neurons. Mol Cell Biol (2000) 1.39
Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum (2002) 1.38
Tumor markers in neuroendocrine tumors. Digestion (2000) 1.38